APYX Share Price | Apyx Medical Corp. Stock Analysis & Recommendation

Q: Is Apyx Medical Corp. technically bullish or bearish?

As of 19 August 2025, the technical trend for Apyx Medical Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum and weekly Bollinger Bands also signaling bullish conditions. However, the weekly MACD and KST are mildly bearish, and the monthly RSI is bearish, which suggests some caution. In terms of performance, Apyx Medical Corp. has outperformed the S&P 500 significantly over the past year with a return of 113.33% compared to the S&P 500's 17.14%, but it has underperformed over the longer three and five-year periods.

Q: How big is Apyx Medical Corp.?

Market Cap: As of Jun 18, Apyx Medical Corp. has a market capitalization of 66.52 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Apyx Medical Corp. reported net sales of 47.29 million and a net profit of -20.14 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 14.21 million and total assets of 64.84 million.

Q: What does Apyx Medical Corp. do?

Overview:Apyx Medical Corporation is an energy-based medical device company engaged in the design, development, and manufacturing of electrosurgical equipment within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot:Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 66.52 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.33 Return on Equity: -191.62% Price to Book: 6.33Contact Details:Address: 5115 Ulmerton Rd, CLEARWATER FL: 33760-4004 Tel: 1 727 3842323 Website: https://apyxmedical.com/

Q: Should I buy, sell or hold Apyx Medical Corp.?

Based on the current situation of Apyx Medical Corp., it would be advisable to hold your position in the stock rather than buy or sell at this time. The company has shown poor long-term growth, with an operating profit growth rate of only 5.78% over the past five years. While there were some positive results reported recently, including a decrease in raw material costs and a slight improvement in pre-tax and net profits, the overall picture remains concerning. The company is experiencing negative EBITDA, which indicates ongoing financial challenges. Additionally, the stock has generated no return over the past year, and profits have declined by 1.6%.On a more positive note, the high institutional ownership at 58.19% suggests that knowledgeable investors are closely monitoring the company's fundamentals. This could provide some stability, but given the risks involved, holding your investment seems to be the most prudent course of action for now.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

66.09 k

Shareholding (Mar 2026)

FII

3.22%

Held by 18 FIIs

DII

96.78%

Held by 14 DIIs

Promoter

0.00%

Is Apyx Medical Corp. technically bullish or bearish?

20-Sep-2025

As of August 19, 2025, Apyx Medical Corp. shows a mildly bullish trend with strong daily moving averages, though caution is advised due to mixed indicators, and it has significantly outperformed the S&P 500 over the past year but underperformed over three and five years.

View full answer

How big is Apyx Medical Corp.?

22-Jun-2025

As of Jun 18, Apyx Medical Corp. has a market capitalization of 66.52 million, with net sales of 47.29 million and a net profit of -20.14 million over the last four quarters.

View full answer

What does Apyx Medical Corp. do?

22-Jun-2025

Apyx Medical Corporation is a micro-cap company that designs and manufactures electrosurgical equipment in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $9 million and a net loss of $4 million.

View full answer

Who are in the management team of Apyx Medical Corp.?

22-Jun-2025

As of March 2022, the management team of Apyx Medical Corp. includes Andrew Makrides (Independent Chairman), Charles Goodwin (CEO), John Andres (Independent Vice Chairman), Lawrence Waldman (Lead Independent Director), and several Independent Directors: Minnie Baylor-Henry, Michael Geraghty, and Craig Swandal. They oversee the company's strategic direction and operations.

View full answer

Should I buy, sell or hold Apyx Medical Corp.?

22-Jun-2025

Compare Apyx Medical Corp. with Similar Stocks

Citius Pharmaceuticals, Inc.Cutera, Inc.Hyperfine, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 10.92% of over the last 5 years

With a growth in Net Sales of 32.45%, the company declared Very Positive results in Mar 26

Risky -

High Institutional Holdings at 48.7%

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 152 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.24

Return on Equity

-76.38%

Price to Book

10.47

Revenue and Profits:

Net Sales:

12 Million

(Quarterly Results - Mar 2026)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

11.99%

6 Months

10.78%

1 Year

140.35%

2 Years

202.21%

3 Years

-40.95%

4 Years

-30.92%

5 Years

-60.59%

Apyx Medical Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

13.78%

EBIT Growth (5y)

10.92%

EBIT to Interest (avg)

-12.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.33

Sales to Capital Employed (avg)

1.04

Tax Ratio

1.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

48.70%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

10.47

EV to EBIT

-24.17

EV to EBITDA

-26.90

EV to Capital Employed

8.62

EV to Sales

2.95

PEG Ratio

Dividend Yield

ROCE (Latest)

-35.66%

ROE (Latest)

-76.38%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 11 Schemes (12.03%)

Foreign Institutions

Held by 18 Foreign Institutions (3.22%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 32.98% vs -7.84% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 50.00% vs 44.74% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12.50",
          "val2": "9.40",
          "chgp": "32.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-2.90",
          "chgp": "75.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-4.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-72.90%",
          "val2": "-323.50%",
          "chgp": "25.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 9.77% vs -8.03% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 52.97% vs -24.87% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.80",
          "val2": "48.10",
          "chgp": "9.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.80",
          "val2": "-18.20",
          "chgp": "68.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.60",
          "val2": "5.90",
          "chgp": "-5.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.10",
          "val2": "-23.60",
          "chgp": "52.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-122.00%",
          "val2": "-391.80%",
          "chgp": "26.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

12.50

9.40

32.98%

Operating Profit (PBDIT) excl Other Income

-0.70

-2.90

75.86%

Interest

1.40

Exceptional Items

0.00

Consolidate Net Profit

-2.10

-4.20

50.00%

Operating Profit Margin (Excl OI)

-72.90%

-323.50%

25.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 32.98% vs -7.84% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 50.00% vs 44.74% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

52.80

48.10

9.77%

Operating Profit (PBDIT) excl Other Income

-5.80

-18.20

68.13%

Interest

5.60

5.90

-5.08%

Exceptional Items

0.00

Consolidate Net Profit

-11.10

-23.60

52.97%

Operating Profit Margin (Excl OI)

-122.00%

-391.80%

26.98%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 9.77% vs -8.03% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 52.97% vs -24.87% in Dec 2024

All Annual Results

Company CV

About Apyx Medical Corp.

Apyx Medical Corp.

Pharmaceuticals & Biotechnology

Apyx Medical Corporation, formerly Bovie Medical Corporation, is an energy-based medical device company. The Company is engaged in the design, development and manufacturing of electrosurgical equipment by producing equipment for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies. It operates through two segments: OEM and J-Plasma. It is engaged in developing and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor's offices, surgery centers and hospitals around the world. It also develops J-Plasma, a helium-based plasma surgical product. The J-Plasma system consists of an electrosurgical generator unit, a handpiece and a supply of helium gas. Its products are marketed through brands, including Aaron, DERM, IDS and ICON, and on a private label basis to distributors around the world. It offers products in electrosurgery, cauteries and other products categories.

Company Coordinates

Company Details

5115 Ulmerton Rd , CLEARWATER FL : 33760-4004

Tel: 1 727 3842323

https://apyxmedical.com/

Registrar Details